Document is current
Any future updates will be listed below
-
Authors
Steendam, Christi M. J.
Meijers, Ruud W. J.
Atmodimedjo, Peggy
van Dijk, Lisette
van der Leest, Cor
van Loenhout, Keetie C. J.
van ’t Westeinde, Susan C.
Dumoulin, Daphne W.
Hanselaar, Wessel E. J. J.
Paats, Marthe S.
de Jonge, Evert
van Schaik, Ron H. N.
von der Thüsen, Jan H.
Aerts, Joachim G. J. V.
Dingemans, Anne-Marie C. https://orcid.org/0000-0001-6105-182X
Dubbink, Hendrikus Jan https://orcid.org/0000-0002-2160-5207
-
Funding
Funding for this research was provided by:
AstraZeneca, The Netherlands (2604937054)
- License Information
-
More Information
Article History
Received: 30 April 2025
Accepted: 30 March 2026
First Online: 8 April 2026
Declarations
:
: CS: no conflict of interestRM: no conflict of interestPA: no conflict of interestLvD: no conflict of interestCL: no conflict of interestKL: no conflict of interestSW: no conflict of interestDD: Honoraria and advisory boards for MSD, Amgen, AstraZeneca, BMS, Roche, Pharmamar. (personel and institution)WH: no conflict of interestMP: received consulting Advisory Boards: Amgen, Eli Lilly, Janssen, Merck, Pfizer all paid to insituteEJ: no conflict of interestRS: no conflict of interestJT: no conflict of interestJA: A received institutional research grants from AstraZeneca, Danone, Genmab and consulting fees from AstraZeneca, MSD, Danone, CureVac and speakers fees from BMS, MSD, Eli-Lilly and has issued patents for allogenic tumor cell lysate, combination immune-oncology drug, biomarker for immunotherapy and unpaid leadership role as Treasurer of IASLC and board member of IMIG and stock options in AmpheraAD: has received institutional consulting fees from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi, Johnson&Johnson, Pfizer, Roche, Abbvie, Mirati and received institutional speaker fees from Amgen, Eli Lilly, Johnson&Johnson and institutional fees for IDMC from Roche, Takeda and institutional fees for steering committee participation from Roche, Eli Lilly, Amgen and unpaid leadership as chair EORTC lung cancer groupHD: received institutional grants from AstraZeneca, MSD and personal speaker fees from AstraZeneca, MSD, GSK, BMS, Johnson&Johnson, Roche, Illumina and institutional support for attending a meeting from OncoDNA and personal fees for Advisory boards from Astellas, Abbvie, AstraZeneca, Janssen, MSD and institutional equipment/materials from Illumina, OncoDNA, HederaDx.
: The Medical ethical committee of the Erasmus MC approved this study but waived the need for informed consent. However, patients provided local consent for use of their (anonymized) data.
